Cotiviti to Share Strategies for Risk Adjustment Excellence at RISE West 2022 Conference

Cotiviti and health plan executives will discuss how to intelligently drive member interventions and achieve premium accuracy SALT LAKE CITY–(BUSINESS WIRE)–Cotiviti, a leader in data-driven healthcare solutions, will present on optimizing health plan risk adjustment programs at the RISE West conference in Los Angeles, taking place August 31–September 2, 2022. Cotiviti’s RaeAnn Grossman, executive vice … [Read more…]

Ontrak Names James Messina to its Board of Directors

HENDERSON, Nev.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by … [Read more…]

Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

– Clinical milestone marks initiation of first ever novel psilocybin analog to enter clinical development – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for … [Read more…]

Global PCR and Realtime PCR testing Market Research Report 2022: A $24.61 Billion Market by 2026 – Long-term Forecasts to 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global PCR And Realtime PCR testing Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global PCR and realtime PCR testing market is expected to grow from $18.5 billion in 2021 to $19.64 billion in 2022 at a compound annual growth rate (CAGR) of 6.2%. The market is expected to grow … [Read more…]

MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids

CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), today announced that it has been selected to conduct an oral presentation covering the novel THIO platform at the XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids, which will be taking place in Stockholm, Sweden on … [Read more…]

Global Molecular Diagnostics Devices and Equipment Market Report 2022: A $46.87 Billion Market in 2026 – Long-term Forecast to 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Molecular Diagnostics Devices And Equipment Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global molecular diagnostics devices and equipment market is expected to grow from $24.19 billion in 2021 to $27.91 billion in 2022 at a compound annual growth rate (CAGR) of 15.3%. The market is expected to grow … [Read more…]

Together Women’s Health Expands into Illinois with the Affiliation of Multiple Practices and Names a New Chief Medical Officer

DETROIT–(BUSINESS WIRE)–Together Women’s Health (“TWH” or “the Company”) is pleased to announce it has entered the Illinois market with the affiliation of both Northwestern Specialists for Women (“NSW”) and North Shore Associates in Gynecology and Obstetrics (“NSAGO”), adding 22 providers and three locations to the TWH network. Together Women’s Health is a women’s health focused … [Read more…]

Mannatech Declares Second Quarter 2022 Dividend

FLOWER MOUND, Texas–(BUSINESS WIRE)–Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend of $0.20 per share of common stock, payable on Wednesday, September 28, 2022, to shareholders of record at the close of business on … [Read more…]

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients

– Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the six treated patients – The five longest treated patients exhibited elevated α-Gal A activity, ranging from nearly 3-fold to nearly 17-fold above mean normal, up to 15 months as at the last date of measurement – One patient … [Read more…]

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

Vivani will be traded under the new ticker (Nasdaq: VANI) LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc.(NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, … [Read more…]